A Phase 2 interventional study of CIN-102 Dose 1 and CIN-102 Dose 2 in Diabetic Gastroparesis, sponsored by CinDome Pharma, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-08-10.
Sponsored by CinDome Pharma, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.
Among the 184 studies in Gastroparesis with a site in United States, this one is the 128th largest by enrollment of the 136 interventional ones that give a count, is one of 12 that started in 2020, is one of 38 in phase 2, and was the 113th registered.
323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.
Browse Gastroparesis studies →33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:
Evan (Huiliang) Wang · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–65
Viral N. Shah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 42 · Phase 3 14 · Phase 4 6
First in 2002; this study’s year is marked. 12 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 42 across 215 interventional studies indexed under Gastroparesis.
Median enrollment 36 across the 136 interventional studies, 108 across the 39 observational. Of the 124 that completed or were terminated, 63 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
55 of 184 have an industry lead sponsor. The 10 most frequent:
CinDome Pharma, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
CinDome Pharma, Inc. has 4 studies filed under Gastroparesis — fewer than ten, so there is no comparison to draw.
14 of the studies in Gastroparesis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01696734Phase 3M.D. Anderson Cancer CenterDomperidone in Treating Patients With Gastrointestinal Disorders | 2027-10-31 |
| NCT04506593Indiana UniversityIndiana University Gastrointestinal Motility Diagnosis Registry | 2026-11 |
| NCT06046833Samita GargContinuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes | 2026-12 |
| NCT02165059Indiana UniversityGI Neuromuscular Pathology Prospective Registry | 2026-12 |
| NCT04282317Indiana UniversityMagnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 184 studies in Gastroparesis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis. The population for this study is adult patients 18 to 70 years old with Type 1 or Type 2 diabetes and a diagnosis of diabetic gastroparesis. The study will consist of two cohorts with approximately 15 subjects in each cohort.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CIN-102 tablets by mouth twice daily for 14 days
Drug: CIN-102 Dose 1
Placebo tablets by mouth twice daily for 14 days
Drug: Placebo for CIN-102
CIN-102 tablets by mouth twice daily for 14 days
Drug: CIN-102 Dose 2
Placebo tablets by mouth twice daily for 14 days
Drug: Placebo for CIN-102
Drug pages: CIN-102 · Deudomperidone
Deuterated domperidone (deudomperidone)
Drug pages: CIN-102 · Deudomperidone
Deuterated domperidone (deudomperidone)
Placebo
To Evaluate the Change From Baseline in Gastric Percentage Retention of a Radiolabeled Meal After Dosing CIN-102 in Patients With Diabetic Gastroparesis.
Time frame: Baseline to Day 14
To Evaluate the Incidence of Treatment-emergent Adverse Effects as Measured by Safety Laboratory Data and Patient Reported Events.
Time frame: Screening to Day 20
To Assess the Effect of CIN-102 on Antral Contractility as Measured by Dynamic Antral Scintigraphy (DAS), a Non-invasive Technique for the Assessment of Post-prandial Gastric Contractions Will be Used to Evaluate Antral Motility.
Time frame: Baseline to Day 14
To Assess the Effect of CIN-102 on Gastric Accommodation to be Evaluated Using Data Captured During the Total-stomach Gastric Emptying Study to Measure Food Retention in the Stomach During the First Two Post-prandial Hours.
Time frame: Baseline to Day 14
To Asses the Change From Baseline in ANMS GCSI-DD Total Scores
Time frame: Day -14 to 14
To Assess the Change From Baseline in ANMS GCSI-DD Subscale Scores
Time frame: Day -14 to 14
To Assess the Change From Baseline in Symptom Severity as Measured by the PAGI-SYM
Time frame: Baseline to Day 14
To Assess the Change in Baseline of the Clinical Grading Assessment Scale
Time frame: Baseline to Day 14
| Milestone | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 |
|---|---|---|---|---|---|
| Started | 2 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 2 | 0 | 0 | 0 | 0 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Approximately one month.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CIN-102 Tablets Dose 1 | — | — | — |
| Placebo for CIN-102 Dose 1 | — | — | — |
| CIN-102 Dose 2 | — | — | — |
| Placebo for CIN-102 Dose 2 | — | — | — |
Two patients entered the Screening Period. No patients were randomized to the Treatment Period.
| Age, Categorical(Participants) | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | — | — | — | — | 0 |
| Between 18 and 65 years | 2 | — | — | — | — | 2 |
| >=65 years | 0 | — | — | — | — | 0 |
| Sex: Female, Male(Participants) | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 | Total |
|---|---|---|---|---|---|---|
| Female | 1 | — | — | — | — | 1 |
| Male | 1 | — | — | — | — | 1 |
| Ethnicity (NIH/OMB)(Participants) | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | — | — | — | — | 1 |
| Not Hispanic or Latino | 1 | — | — | — | — | 1 |
| Unknown or Not Reported | 0 | — | — | — | — | 0 |
| Race (NIH/OMB)(Participants) | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 2 | 0 | 0 | 0 | 0 | 2 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Screening Period | CIN-102 Tablets Dose 1 | Placebo for CIN-102 Dose 1 | CIN-102 Dose 2 | Placebo for CIN-102 Dose 2 | Total |
|---|---|---|---|---|---|---|
| United States | 2 | — | — | — | — | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2020 to primary completion in Mar 2020, 1 month.
Results were first posted in Aug 2021, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CIN-102 · Deudomperidone
CinDome Pharma, Inc.